Drug improves weight, HbA1C in patients with or without diabetes

11/11/2013 | MedPage Today (free registration)

Data on obese and overweight patients with or without diabetes showed those who took the weight-loss drug Qsymia shed more pounds at 56 weeks on either low or high doses of the drug compared with a placebo group. Diabetes patients who took the drug attained a mean HbA1C decline of 1.6%, compared with only 1.2% in the placebo arm, researchers reported at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC